CRWV vs MRK: Which Is the Better Buy?
Side-by-side comparison of CoreWeave, Inc. Class A Common Stock and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
CoreWeave, Inc. Class A Common Stock · Technology
$86.76
+45.0% upside to fair value
Med Conviction
Grade B
VS
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
CRWV has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWV |
MRK |
| Current Price |
$86.76 |
$147.17 |
| Fair Value Estimate |
$125.80 |
$141.07 |
| Upside to Fair Value |
+45.0%
|
-4.1%
|
| Market Cap |
$47.3B |
$363.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
36.3x
|
29.6x
|
| Price / Sales |
6.2x
|
5.5x
|
| Price / FCF |
—
|
22.6x
|
| Revenue Growth YoY |
+112.3%
|
+5.1%
|
| Gross Margin |
67.4%
|
75.4%
|
| Operating Margin |
-3.0%
|
16.7%
|
| Return on Equity |
-45.4%
|
6.6%
|
| Dividend Yield |
0% |
2.31% |
| FCF Yield |
—
|
4.42%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
CoreWeave operates a specialized GPU cloud platform purpose-built for generative AI workloads, offering high-performance GPU and CPU compute, storage, networking, and managed services to large enterprises from bare-metal and virtual server options. The business is growing explosively, with revenue up 112.3% year over year in the most recent quarter and a TTM gross margin of 67.4%, but it is doing…
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Accumulation Zones
| Metric |
CRWV |
MRK |
| Zone Low |
$94.35 |
$105.80 |
| Zone High |
$106.93 |
$119.91 |
| In Buy Zone? |
Yes
|
No
|